Aptahem is developing the drug candidate Apta-1 as an emergency treatment for sepsis, a life-threatening condition that is relatively unknown to the general public. BioStock had the opportunity to talk about this and what place Apta-1 might play in future sepsis care with the company's scientific advisors, Anders Bylock and Mats Eriksson .

Aktiehistorik, Aptahem. Aptahem har fastställt teckningskursen i företagets teckningsoptionsprogram TO 5 till 1,40 kronor. 2020. De som på avstämningsdagen

Aptahem | 136 följare på LinkedIn. Aptahem develops pharmaceuticals for the treatment of life-threatening conditions caused by coagulation and inflammation | Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early … 2021-4-13 · Aptahem AB (Spotlight: APTA) is a biotechnology company that develops aptamer-based drugs for the treatment of life-threatening conditions where coagulation and inflammation interact in … * APTAHEM ENTERS A COLLABORATION WITH UNIVERSITY HEALTH NETWORK IN CANADA TO TEST APTA-1 IN A CORONAVIRUS MODEL Source text for Eikon: Further company coverage: Biotechnology company Aptahem, that develops its drug candidate Apta-1 for the treatment of life-threatening organ and tissue damage caused by sepsis, was recently able to announce an oversubscribed rights issue that strengthens the company ahead of its continued development. Aptahem AB is a manufacturer of biological products.

The company is engaged in developing bio-copy a blockerarmolekyl (inhibitor) of the proteins that stick together the cells that eventually grows to a blood clot and subsequent stroke. LGC and Aptahem combine on first large-scale production campaign of Apta-1 . Aptahem AB, a leading developer of aptamer-based drugs, has announced that the company is now starting large-scale manufacturing after LGC completed the Process Development (PD) work enabling larger Pilot scale production campaigns of Apta -1. Aptahem develops aptamer-based drugs for the treatment of life-threatening conditions where coagulation and inflammation interact in the disease process. Apta-1, the company's leading drug candidate, is an emergency medicine that is developed with the aim of stopping the organ and tissue damage that leads to the very high mortality rate for Aptahem AB is a pre-clinical company. The Company develops drugs to treat and prevent diseases caused by blocked blood vessels. Aptahem focuses on synthetic biomolecules with anti-coagulant In order to finance the continued development towards clinical studies, Aptahem is currently raising just over 32 MSEK in a rights issue of units.

2021-03-30 · Aptahem AB ("Aptahem" eller "Bolaget") genomförde under oktober 2020 en företrädesemission av units där varje unit bestod av tre (3) aktier, två (2) teckningsoptioner serie TO 5 och en (1) teckningsoption serie TO 6. Totalt emitterades 11 974 376 teckningsoptioner serie TO 5 vederlagsfritt

Aptahem Finans AB (559060-1448). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.

Select newer press release. ↓, Select older press release. ←, Navigate backwards. →, Navigate forward. Enter, Navigate to line in focus. Tab, Focus next link.

i kategorin Aptahem har fastställt teckningskursen i företagets teckningsoptionsprogram TO 5 till 1,40 kronor.

Aptahem's CEO, Mikael Lindstam joined Edison at DNB's 4th North American Life Science conference to discuss highlights from 2019 and what Den 1 mars tillträder Luiza Jedlina som forskningschef, CSO, på det Malmöbaserade biotechbolaget Aptahem. Hon har arbetat som program Undertecknad anmäler sig härmed för teckning av följande antal units i Aptahem AB (publ) till en kurs om 4,00 SEK per unit. Varje unit består Aptahem (publ) är ett biotekniskt bolag som utvecklar Aptahem meddelar idag att samarbetet med Cardiovascular Research Centre (CVRC) Forskningsbolaget Aptahem uppger att många insynspersoner som anställda, styrelseledamöter och storägare tecknar units i den förestående Aptahem · Aptic · AQ Group · Aqua Bio Technology · AqualisBraemar · Arbetsförmedlingen · Arbetskraft · Arbetskraftskostnader · Arbetslöshet · Arbetsmarknad samband med DanCann Pharma A/S noteringsemissionen 2 oktober, 2020 Corpura Fondkommission AB är finansiell rådgivare i samband med Aptahem ABs Angler Gaming, Annexin Pharmaceuticals, Anoto Group, Apetit, AppSpotr, Aptahem, AQ Group, Arbona A, Arbona B, ArcAroma B, Archelon B, Arcoma, Arctic Det mäeks knappt Follicum planerar emission inför notering på AktieTorget Med BTU den 6 november 2017 – Aptahem Buniträtter avanza. dag Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved.
Can speaker wire shock you

A similar mechanism occurs in cardiovascular diseases where a combination of coagulation and inflammation are involved. Aptahem develops aptamer-based drugs for the treatment of life-threatening conditions where coagulation and inflammation interact in the disease process. Apta-1, the company's leading drug candidate, is an emergency medicine that is developed with the aim of stopping the organ and tissue damage that leads to the very high mortality rate for Aptahem General Information Description. Aptahem AB is a pre-clinical company. The company is engaged in developing bio-copy a blockerarmolekyl (inhibitor) of the proteins that stick together the cells that eventually grows to a blood clot and subsequent stroke.

Den 15 april 2021 avslutades nyttjandeperioden och totalt nyttjades 11 349 069 teckningsoptioner serie TO 5 för teckning av lika många aktier, vilket motsvarar en nyttjandegrad om cirka 95 procent. Aptahem utvecklar aptamerbaserade läkemedel för behandling av akuta livshotande tillstånd där koagulation och inflammation samverkar i sjukdomsprocessen.
Kurser dagtid göteborg

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of pr

Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar. Aptahem Develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Aptahem AB, Malmö (Malmö, Sweden). 111 likes · 1 was here. Aptahem is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a 2021-03-30 · Aptahem AB ("Aptahem" eller "Bolaget") genomförde under oktober 2020 en företrädesemission av units där varje unit bestod av tre (3) aktier, två (2) teckningsoptioner serie TO 5 och en (1) teckningsoption serie TO 6.